Icatibant Hikma (Icatibant)

Icatibant works by selectively antagonizing the bradykinin B2 receptor on vascular endothelial cells. This prevents bradykinin from triggering vasodilation and increased vascular permeability, which are the primary mechanisms behind the swelling seen in hereditary angioedema.

The dose and administration schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition and regulatory guidelines. Clinicians tailor the regimen to achieve optimal control of angioedema symptoms.

Safety data for icatibant in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified prescriber.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Icatibant is a small‑molecule bradykinin B2 receptor antagonist, whereas the main alternative class consists of plasma‑derived or recombinant C1‑inhibitor concentrates. Icatibant targets the downstream mediator (bradykinin) directly, offering rapid symptom relief, while C1‑inhibitor products replace the deficient protein and may have a broader effect on the complement cascade.

Icatibant Hikma must be stored refrigerated at 2‑8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the product. If a brief temperature excursion occurs, consult the product’s stability guidelines before use.

The medication is supplied as an injectable solution for intravenous administration. It is typically given by a healthcare professional in a clinical setting, following aseptic technique and the dosing instructions provided by the prescriber.

The most serious adverse reactions include anaphylaxis or severe hypersensitivity, sudden hypotension, and life‑threatening angioedema of the face, lips or airway. Prompt recognition and emergency treatment are essential if any of these events occur.

Patients with a known hypersensitivity to icatibant or any of its excipients should avoid the product. Caution is also advised for individuals with severe renal or hepatic impairment, and those taking ACE inhibitors or other agents that increase bradykinin levels.